Roivant Sciences stock
Price history
+92.27% over the period1 year: from $20.56 (November 13, 2025) to $39.53 (November 13, 2026), +92.27%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $39.53 |
| October 30, 2026 | $36.91 |
| September 30, 2026 | $36.57 |
| August 31, 2026 | $34.64 |
| July 31, 2026 | $33.91 |
| June 30, 2026 | $35.39 |
| May 29, 2026 | $29.99 |
| April 30, 2026 | $28.53 |
| March 31, 2026 | $27.70 |
| February 27, 2026 | $28.94 |
| January 30, 2026 | $21.62 |
| December 31, 2025 | $21.70 |
| November 28, 2025 | $20.81 |
| November 13, 2025 | $20.56 |
At a glance
The company
Clinical-stage biopharmaceutical company developing medicines for autoimmune, inflammatory, and rare diseases
Latest results
Quarter to September 30, 2026 · EPS -$0.18 (estimate -$0.37)
TickerLandia's take on Roivant Sciences
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−6.99% from the 52-week high
Analysts · 13 analysts
Average target$48.91+23.73% vs. price
Buy 11 · Hold 2 · Sell 0 · Strong buy
TickerLandia Fingerprint: Roivant Sciences
Compared with similar companies: very strong momentum, very high financial strength, and very low profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Profitabilityvery low17
How much it earns on revenue and capital.
Metric Value Position in group Net margin 0.0% 30 Gross margin 0.0% 6 ROE −8.5% 25 Operating marginabove 100%: likely one-off items −3,226.3% 7 ROA −16.5% 16 Earnings stabilityvery low17
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5,842.6% 4 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −19.78% 43 Revenue growth (year over year) +2,135.60% 97 Average revenue growth (3 years) −36.01% 4 Financial strengthvery high85
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.02 76 Current ratio 15.6 94 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong88
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +92.27% 97 Distance from 200-day average +22.34% 90 Relative strength (3 months) +12.38% 78 Relative strength (6 months) +33.18% 88 Riskaverage58
How much the price swings.
Metric Value Position in group Volatility (60 days) 54.1% 81 Beta (1 year) 1.13 68 Maximum drawdown (12 months) 20.2% 27
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Roivant Sciences is cheaper than similar companies
Roivant Sciences's Price/book: 6.29, −13% against the median of a group of 11 similar companies (7.20).
Compared with 11 similar companies
| Metric | Roivant Sciences | Position in the group | Band |
|---|---|---|---|
| Operating margin | -17,875.4% | Low | |
| ROE | -8.5% | Low | |
| Debt/equity | 0.02 | Low | |
| Price/book | 6.29 | Middle | |
| Net margin | -3,535.0% | Low |
Grey band: the middle half of the group; tick: the median; dot: Roivant Sciences. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.44M
Latest quarter · Q2 2026
Net income
-$189.84M
Latest quarter · Q2 2026
Quarterly net margin
-13,164.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $26.39B
- EPS
- -$0.59
- Volume
- 6.57M
- Daily trading
- €295.58M
How Roivant Sciences is changing
All resultsRevenue fell 19.1% a year on average over the last 5 years
Operating margin fell from −2,565.9% to −15,495.2%
Less cash than profit: free cash flow equal to -61% of net income
Returns
Roivant Sciences returns
$1,000 invested in Roivant Sciences 5 years ago, on November 15, 2021, would be worth $4,892 today: +389.23% in total, +37.43% per year. This is the price return only: dividends are excluded.
| Period | Roivant Sciences | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +18.53% | −3.12% | $1,185 |
| 6 months | +35.28% | +1.58% | $1,353 |
| Year to date | +82.17% | +10.46% | $1,822 |
| 1 year | +92.27% | +12.23% | $1,923 |
| 3 years | +336.80% | +71.41% | $4,368 |
| 5 years | +389.23% | +61.48% | $4,892 |
Over the last 6 months it has done better than 73% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Roivant Sciences: technical analysis
Roivant Sciences is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.5% below its all-time closing high ($41.85, November 11, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 57
- Between 30 and 70
- vs 200-session average
- +22.34%
Support and resistance
Price areas where Roivant Sciences has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$39.53
- Support$38.19−3.39%4 touches, last on October 22, 2026
- Support$35.63−9.87%2 touches, last on November 3, 2026
- Support$33.05−16.39%5 touches, last on October 14, 2026
Volatility and risk
Over the last year it has moved roughly in line with the S&P 500.
- Beta (1 year) vs S&P 500
- 1.13
- Volatility (60 sessions, annualised)
- 54.1%
- Largest fall in the last year
- −20.23%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Roivant Sciences: seasonality
Average monthly price change over 6 years
Over the last 6 years, the strongest month for Roivant Sciences has been December: +23.19% on average, positive in 4 years out of 5. The weakest has been March: −8.76% on average, positive in 0 years out of 6. November, the current month, has been positive in 4 years out of 5 (+2.51% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −7.16% | −3.14% | 2 of 6 |
| February | +5.26% | −1.85% | 2 of 6 |
| March | −8.76% | −6.96% | 0 of 6 |
| April | +2.16% | +3.21% | 5 of 6 |
| May | +3.55% | +2.51% | 3 of 6 |
| June | +4.26% | +2.29% | 5 of 6 |
| July | +2.68% | +0.50% | 4 of 6 |
| August | +1.05% | +1.28% | 4 of 6 |
| September | +2.02% | −2.35% | 3 of 6 |
| October | +8.61% | +0.51% | 4 of 6 |
| November | +2.51% | +4.28% | 4 of 5 |
| December | +23.19% | +17.47% | 4 of 5 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Roivant Sciences and its competitors
Headquartered in London and founded in 2014, Roivant Sciences Ltd. develops medicines and related technologies aimed at immune-mediated and cardiopulmonary conditions. Its clinical pipeline is built around antibodies such as IMVT-1402 and batoclimab, the small molecule brepocitinib, and mosliciguat, an inhaled sGC activator that is the lead program and targets pulmonary hypertension linked to interstitial lung disease. These candidates are still in development, with target indications that include Graves' disease, rheumatoid arthritis, myasthenia gravis, thyroid eye disease and dermatomyositis.
- Headquarters
- London, United Kingdom
- Employees
- 721
- Founded
- 2014
- Chief executive
- Matthew Gline
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Roivant SciencesROIV | $26.39B | -17,875.4% | — | +35.28% |
| InsmedINSM | $26.58B | -41.7% | — | +2.69% |
| IncyteINCY | $24.66B | 32.2% | 61.7 | +22.41% |
| Revolution MedicinesRVMD | $37.27B | -853.0% | — | +14.91% |
| Alnylam PharmaceuticalsALNY | $22.11B | 19.5% | 8.34 | −43.38% |
| BioNTechBNTX | $21.22B | -55.4% | — | −7.19% |
Same industry or related industries, similar size. Compare Roivant Sciences with its competitors · Full profile
